jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Pharmacy PracticeNOW IN
Article

First Middle Eastern-Based Gut Microbiota Study: Implications for Inflammatory Bowel Disease Microbiota-Based Therapies

Mamoon M. D. Al-Rshaidat1★, Shaima Al-Sharif1, Tarek A. Tamimi2, Munir A. Al-Zeer3, Jehad Samhouri2, Ahmad R. Alsayed4, Yaser M. Rayyan2★ Corresponding author

  1. 1Laboratory for Molecular and Microbial Ecology (LaMME), Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.
  2. 2School of Medicine, The University of Jordan, Amman, Jordan.
  3. 3Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.
  4. 4Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.

CORRESPONDENCE

Mamoon M. D. Al-Rshaidat

Laboratory for Molecular and Microbial Ecology (LaMME), Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.

m.rshaidat@ju.edu.jo

Received: 17-06-2024; Accepted: 15-08-2024.

Volume 23, Issue 3 · pp. 3202 · PUBLISHED 28 August 2025 · DOI: 10.18549/PharmPract.2025.3.3202

View on PP original site ↗

ABSTRACT

Objective: To investigate the differences in gut microbiota composition between healthy individuals and those with inflammatory bowel disease (IBD) in Jordan and to understand how these differences may contribute to the pathogenesis of IBD. Methods: This study involved the comprehensive analysis of 20 gut microbiota samples from diverse populations in Jordan. Using 16S rRNA sequencing, the gut microbiome composition of healthy individuals was compared to that of individuals with IBD. The analysis focused on microbial diversity and the relative abundance of specific bacterial taxa. Results: The study revealed significant disparities in the gut microbiota composition between healthy individuals and those with IBD. IBD patients exhibited reduced microbial diversity. There was a notable decrease in the abundance of beneficial taxa such as Firmicutes and Bacteroidetes, specifically the families Erysipelotrichaceae, Ruminococcaceae, and Lachnospiraceae. IBD patients showed elevated levels of potentially harmful bacteria, particularly the Proteobacteria phylum. Three bacterial classes, Pseudomonas, Clostridia, and Escherichia, were significantly increased in IBD patients. Beneficial genera such as Faecalibacterium prausnitzii, Bifidobacterium, Blautia, Coprococcus, and Bacteroides dorei were more prominent in healthy controls, highlighting their roles in maintaining gut health and anti-inflammatory properties. Conclusion: The findings underscore a significant association between gut microbiota dysbiosis and IBD. IBD patients in Jordan exhibited lower microbial diversity and an imbalance favoring harmful bacterial taxa. These insights into the gut microbiota composition offer a valuable understanding of IBD pathogenesis and suggest that therapeutic strategies targeting the gut microbiome could be promising for managing the disease. Further research into the interplay between gut microbiota and the immune system is essential for developing novel IBD treatments.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Al-Rshaidat, M. M. D., Al-Sharif, S., Tamimi, T. A., Al-Zeer, M. A., Samhouri, J., Alsayed, A. R., & Rayyan, Y. M. (2025). First Middle Eastern-Based Gut Microbiota Study: Implications for Inflammatory Bowel Disease Microbiota-Based Therapies. Pharmacy Practice, 23(3), 3202. https://doi.org/10.18549/PharmPract.2025.3.3202